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Abstract
A foot-and-mouth disease virus (FMDV) field variant, isolate C-S30 (also named C1-Barcelona), is known to contain four
changes within the main antigenic site A (GH loop of capsid protein VP1, residues 136–150), at least one of which (Leu147Val)
involves a highly conserved position, critical for antibody recognition in the reference strain C-S8c1. However, immunoenzymatic
analysis of FMDV C-S30 showed it was recognised by 4C4, a monoclonal antibody that specifically targets site A. This
remarkable behaviour has led us to analyse the individual and combined contributions of the four mutations to the antigenicity
of C-S30, by surface plasmon resonance (SPR) and enzyme-linked immunosorbent assay (ELISA) studies of pentadecapeptides
displaying all possible combinations of the four replacements. Analysis of this family of C-S30-derived analogues shows a certain
level of antibody recognition by SPR. In addition, SPR data suggest that kinetic rate constants provide an indirect measure, on
the one hand, of paratope accessibility (association rate constant) and, on the other hand, of peptide fitness to the same paratope
(dissociation rate constant). © 2001 Elsevier Science Ltd. All rights reserved.
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1. Introduction
Foot-and-mouth disease virus (FMDV), an aph-
thovirus from the Picornairidae family, causes the
economically most important disease of farm animals.
The very high antigenic and genetic variability of the
virus is a major obstacle to the eradication of the
disease. Conventional inactivated virus-based vaccines
protect only against homologous viruses and have been
related to several disease outbreaks in the field (Pereira,
1981; Mateu et al., 1988; Gebauer et al., 1988; Kitching
et al., 1988; Domingo et al., 1990).
Most anti-FMDV neutralizing antibodies are di-
rected towards the GH loop of capsid protein VP1,
Abbreiations: AA, amino acid residue; AAA, amino acid analysis; AM, 2-[4-aminomethyl-(2,4-dimethoxyphenyl)]phenoxyacetic acid (linker);
CA, analyte concentration; DMF, N,N -dimethylformamide; EDC, N-ethyl-N -dimethylaminopropylcarbodiimide; EID, enzyme-linked im-
munodot; EITB, enzyme-linked immunoelectrotransfer blot. ELISA, enzyme-linked immunosorbent assay; ESMS, electrospray mass spectrome-
try; Et3SiH, triethylsilane; FMDV, foot-and-mouth disease virus; Fmoc, 9-fluorenylmethoxycarbonyl; HPLC, high performance liquid
chromatography; IC50, 50% inhibition concentration; ka, association rate constant (M
−1 s−1); KA, thermodynamic association constant (M
−1);
kd, dissociation rate constant (s
−1); KD, thermodynamic dissociation constant (M); KLH, keyhole limpet hemocyanin; ks, apparent rate constant
(s−1); MALDI-TOF MS, matrix-assisted laser desorption time-of-flight mass spectrometry; MBHA, p-methylbenzhydrylamine resin; MBS,
m-maleimidobenzoyl-N-hydroxisuccinimide ester; MeCN, acetonitrile; MPLC, medium pressure liquid chromatography; NHS, N-hydroxysuccin-
imide; mAb, neutralising monoclonal antibody; NMM, N-methylmorpholine; PBS, phosphate buffer saline; Req, equilibrium response; RI, bulk
refractive index; Rimmob, immobilisation response; Rmax, maximum response; RU, resonance units; SPPS, solid phase peptide synthesis; SPR,
surface plasmon resonance; tBu, tert-butyl; TBTU, 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate; TFA, trifluoroacetic
acid.
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Table 1
Synthetic peptides reproducing mutations in FMDV C-S30
corresponding approximately to residues 136–150. This
immunodominant site, termed site A, consists of several
overlapping continuous epitopes which have been faith-
fully reproduced by synthetic peptides. Antigenic site A
includes highly conserved residues such as the integrin-
binding Arg–Gly–Asp (RGD) motif or the Leu
residues at positions 144 and 147, all of them critically
involved in cell and antibody recognition events
(Strohmaier et al., 1982; Cheung et al., 1983; Fox et al.,
1989; Mateu et al., 1989, 1990; Martı´nez et al., 1991;
Mateu et al., 1996; Verdaguer et al., 1998).
Site A of FMDV C-S8c1 is mimicked by peptide A15
(Table 1) and the interactions of this peptide with
neutralizing mAbs such as SD6 [raised against C-S8c1
(Mateu et al., 1988)] and 4C4 [raised against C1-Brescia
(Mateu et al., 1988)] have been fully characterized by
means of ELISA, SPR and X-ray crystallographic stud-
ies (Verdaguer et al., 1998; Gomes et al., 2000a,b).
Interactions of A15 with each of these mAbs share
many common features. Indeed, in the crystal state, the
peptide adopts a quasi-cyclic conformation when com-
plexed with the Fab fragment of either mAb, with
substantial induced-fit in both molecules and the RGD
triplet playing a key role in the interaction (Verdaguer
et al., 1998).
On previous genomic studies of FMDV field isolates,
a natural variant, C-S30, was characterized as contain-
ing four mutations in the GH loop (Ala138Thr,
Ala140Thr, Leu147Val and Thr149Ala) rela-
tive to the reference strain C-S8c1 (Mateu et al., 1987,
1988). This viral isolate was neutralized by the site
A-directed mAb 4C4 (Mateu, personal communication)
and its capsid protein VP1 was recognized by the same
mAb in EITB assays (Mateu et al., 1990). This behav-
ior was confirmed on peptide-KLH conjugates repro-
ducing the four mutations of site A (Mateu et al.,
1992). Parallel studies had established that at least one
of the mutations (Leu147Val) was clearly detrimen-
tal for recognition by 4C4 (Carren˜o et al., 1992). At the
time, these findings (one mutation abolishing antigenic-
ity, three additional ones apparently restoring it) were
interpreted in the sense that multiple replacements on
the GH loop of C-S30 were not strictly additive (Mateu
et al., 1992; Carren˜o et al., 1992).
Additional evidence on the antigenicity of C-S30 has
come from recent crystallographic studies showing that
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a site A pentadecapeptide with the four mutations is
capable of forming a complex with 4C4 with a similar
array of interactions than the reference peptide A15
(Ochoa et al., 2000).
To further clarify these issues, we have decided to
quantitate the effects of single and combined mutations
at the four positions of interest within site A. We have
analyzed sixteen peptides with the relevant substitutions
(Table 1) and studied their interactions with site A-spe-
cific mAbs SD6, 4C4 and 3E5 by ELISA and SPR.
Results are totally self-consistent, showing a modest
level of mAb recognition for C-S30 peptides. Addition-
ally, SPR data obtained with this family seems to show
that, while the dissociation rate constant gives a mea-
sure of peptide antigenicity, the association rate con-
stant appears to be related to the particular features of
the antibody paratope.
2. Experimental
2.1. Materials and methods
2.1.1. Peptide synthesis and purification
Peptides (Table 1) were synthesized by SPPS in an
ABIMED AMS 422 multiple peptide synthesizer using
Fmoc/tBu chemistry on an AM-MBHA resin (0.51
mmol/g). The synthesis scale was 0.025 mmol and
couplings were done with four equivalents (eq) of
Fmoc-AA-OH, 4 eq of TBTU and 8 eq of NMM. A
20% piperidine solution in DMF was used for the
deprotection cycles. Peptides were fully deprotected and
cleaved from the resins by treatment with 1 ml of a
95:2.5:2.5 (v/v) TFA/Et3SiH/H2O cocktail for 2 h at
room temperature. The crude peptides were precipi-
tated from the TFA solution by treatment with cold
tert-butyl methyl ether, lyophilized and purified by
MPLC, employing a gradient of 525% MeCN in
water with 0.05% TFA. Purified peptides were satisfac-
torily characterised by AAA, HPLC and ESMS or
MALDI-TOF MS.
2.1.2. Peptide and mAb solutions for SPR analysis
Peptide stock solutions, 2.5 mM in 0.1 M acetic
acid, were prepared and quantitated by AAA. Solutions
for BIAcore analysis were obtained by 1000-fold and
subsequent serial dilutions in HBS. Stock solutions of
mAbs SD6 and 4C4 in PBS with 0.02% sodium azide,
pH 7.3 (supplied by Drs Nu´ria Verdaguer and Wendy
Ochoa), were quantitated by the Pierce BCA Assay.
mAb 3E5 was purified from ascitic fluid (supplied by
Dr Emiliana Brocchi) using a HiTrap Protein A affinity
column (Pharmacia Biotech) and quantitated by UV–
Vis spectroscopy [1 OD280 unit=0.75 mg/ml]. The solu-
tions used for mAb immobilization (in 10 mM acetate
buffer, pH 5.0) had a 5 g/ml final concentration.
2.1.3. Surface plasmon resonance analysis
BIAcore 1000 instrument, sensor chips CM5, HBS
buffer (10 mM Hepes with 0.15 M NaCl, 3.4 mM
EDTA and 0.005% surfactant P20 at pH 7.4), amine
coupling kit (NHS, N-hydroxysuccinimide; EDC, N-
ethyl-N -dimethylaminopropylcarbodiimide) and
ethanolamine were all from Biosensor AB. Immobiliza-
tion of mAbs was performed according to the manufac-
turer’s instructions: a 5 l/min HBS continuous flow
was maintained and the carboxymethyl surface was
activated by a 7-min injection of a solution containing
0.2 M EDC and 0.05 M NHS; biospecific surfaces were
obtained by injecting 35 l of the mAb solutions;
unreacted activated groups were blocked by a 6-min
injection of ethanolamine and remaining non-covalently
bound molecules were washed off with a 3-min pulse of
100 mM HCl for SD6 or 10 mM NaOH for 4C4 and
3E5 surfaces. Final surface densities were typically
around 1500 RU.
All kinetic SPR analyses were run at a 60 l/min
HBS flow and each peptide was injected at six different
concentrations, ranging from 80 to 2500 nM for
SD6, 40 to 1250 nM for 4C4 and 20 to 625 nM
for 3E5 surfaces. Sensorgrams were generated by injec-
tions of peptide solutions with 90 s association steps
followed by 240 s dissociation in running buffer (kinjec-
tion mode). A 90 s pulse of 100 mM HCl or 10 mM
NaOH (SD6 and 4C4/3E5 surfaces, respectively) was
applied to regenerate the surfaces at the end of each
cycle and washing steps were added to avoid carry-
over. The scrambled pentadecapeptide A15scr was in-
jected under the same conditions as a control for
non-specific binding and instrumental drift effects.
Biosensor data were prepared, modeled and fitted by
means of BIAevaluation 3.0.2 software, where calcula-
tions are carried out by numerical integration (Morton
et al., 1995) and global curve fitting is done by non-lin-
ear least-squares analysis (O’Shannessy et al., 1993)
applied simultaneously to the entire data set. The qual-
ity of the fitted data was evaluated by visual compari-
son between calculated and experimental curves as well
as by the magnitudes of the Chi squared parameter and
of the standard errors associated to the experimental
constants.
Some SPR experiments were also run in reverse
order, immobilizing peptide and using mAb as the
soluble reactant. These assays were carried out merely
from a qualitative and comparative point of view and
were not fully optimized. Peptide immobilization was
identical to the one described above for mAbs: 25 l of
peptide solutions (200 g/ml in 10 mM acetate
buffer, pH 5.0) were injected over the activated surfaces
and final immobilization responses (Rimmob) were 170
RU. mAb solutions (in HBS buffer) ranged from 25 to
800 nM (SD6) and from 16 to 500 nM (4C4 and 3E5)
and sensorgrams were run, modeled and fitted as
above.
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Table 2
Kinetic data for the interactions between mAb SD6 and site A peptides, representing all combinations of the four mutations found in FMDV
C-S30 (138T, 140T, 147V, 149A)
2.1.4. Competition ELISA
A fast qualitative competition ELISA screening of
the peptides was performed with the sole purpose of
confirming the peptide ranking withdrawn from SPR
studies.
Each peptide (0.1–242 pmol/well) was made to com-
pete with an A21-KLH conjugate (5 pmol peptide/well;
conjugate prepared by coupling KLH to A21-Cys using
N-hydroxysuccinimide 3-maleimidobenzoyl ester) for
the same mAb, as previously described (Mateu et al.,
1995). Absorbance at 492 nm was determined on a
Labsystems Multiskan RC instrument and corrected by
subtraction of the mean absorbance of three negative
controls (no A21-KLH conjugate, no mAb, and neither
conjugate nor mAb). Average from duplicate series of
readings was expressed as percentage of the maximal
absorbance of positive controls (conjugate+mAb and
no peptide competitor). These data were converted to
IC50s, defined as the concentrations giving 50% of
maximal absorbance. Final antigenicities are expressed
as relative IC50s, normalized to the IC50 of the reference
peptide, A15.
3. Results
3.1. Peptides
Sixteen 15-residue peptides (Table 1) were synthesized,
one representing site A of FMDV C-S8c1 (A15), another
representing the same site of four-point mutant strain
C-S30 (A15S30) and 14 others corresponding to all
possible intermediate (one-, two- and three-point) combi-
nations of the mutations found in FMDV C-S30. A
scrambled sequence pentadecapeptide, A15Scr, was also
prepared as a negative control. All peptides were synthe-
sized by Fmoc-based solid phase methods (Fields and
Noble, 1990; Mateu et al., 1996) and satisfactorily
identified (AAA, ESMS, MALDI-TOF MS) as the target
sequences, with purities always higher than 90% (HPLC).
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Table 3
Kinetic data for the interactions between mAb 4C4 and the peptides under study
3.2. Competition ELISA studies
Competition between plate-bound A21 (KLH conju-
gate) and each peptide in Table 1 in soluble form for
mAbs SD6, 4C4 and 3E5 was qualitatively measured by
ELISA. Single point mutants Ala140Thr and
Thr149Ala were shown to bind effectively to all
three mAbs (Tables 2–4). Mutant Ala138Thr was
not a good competitor (IC5030) for mAb SD6, but its
binding behaviour towards mAbs 4C4 and 3E5 was
rated as good (IC505) and reasonable (5IC5030),
respectively. Mutant Leu147Val was a reasonable
ligand to mAb SD6 but a bad competitor when mAbs
4C4 and 3E5 were employed. The remaining mutants,
corresponding to all possible combinations of the four
mutations, were generally modest competitors. Results
were consistent with an overall additive effect, where
the worse competitors usually included mutations
Ala138Thr and Leu147Val, while the best corre-
sponded to A15Brescia. Peptide A15S30 followed this
same trend (Fig. 1).
3.3. SPR analysis
Although illustrative, data from competition ELISA
did not provide a very good description of the mAb–
peptide interactions, since a number of peptides did not
compete with plate-bound A21 within the concentra-
tion range chosen (1–2420 nM) and thus no IC50s
could be calculated. Therefore, in order to achieve a
fast, direct screening of a fairly large number of FMDV
peptides, we immobilized the three anti-FMDV mAbs
on BIAcore CM5 chips and used the peptides as soluble
analytes. Whenever interactions could not be reliably
measured (denoted as ‘ni’ on Tables 1–4), sensorgrams
had square-wave-like shapes, either due to a mere re-
fractive index jump or to extremely low-affinity. All the
measurable interactions fitted to a pseudo-first-order
1:1 kinetic model (with baseline drift correction when
required) and provided self-consistent results (Schuck
and Minton, 1996). Real-time kinetic data on these
peptide–mAb interactions (Tables 2–4) generally
showed good correlation with ELISA.
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Table 4
Kinetic data for the interactions between mAb 4C4 and the peptides under study
For single-point mutants, similarly to what was ob-
served with competition ELISA, SPR analysis showed
substitutions Ala140Thr and Thr149Ala to be
well tolerated by the three mAbs. This was to be
expected, since both replacements are present in field
isolate C1-Brescia, previously shown to be recognized
by these mAbs. Mutations Ala138Thr and Leu147
Val affected antibody recognition to different extents:
mAb SD6 was more sensitive to Ala138Thr than to
Leu147Val, quite the opposite to mAb 4C4, which
tolerated the first replacement much better than the
second one. Similar effects were observed for mAb 3E5.
These results are consistent with recent crystallographic
studies, where it was found that Ala138 has a higher
percentage of residue contact with mAb SD6 than with
mAb 4C4 (Verdaguer et al., 1998).
Peptides with two or three replacements displayed
antigenicities in agreement with the above pattern (Ta-
bles 2–4). While A15Brescia is the most antigenic pep-
tide of the set, decreases in mAb recognition are seen
whenever mutations Ala138Thr and Leu147Val
are simultaneously introduced. Once again, SPR-
derived affinities correlated well with data from ELISA.
Finally, the four-point mutant pentadecapeptide re-
producing C-S30 site A followed the same trend already
described for the partial mutants. Simultaneous inser-
tion of the Ala138Thr, Ala140Thr, Leu147Val
and Thr149Ala replacements resulted in modest anti-
genic responses towards the three mAbs (Tables 2–4),
with important differences in the dissociation rate con-
stants of the corresponding mAb-peptide complexes
when compared to the reference peptide A15 (Fig.
2(A–B)). A biosensor assay in reverse order (immobi-
lized peptide and mAb as soluble analyte) was per-
formed to further confirm the antigenicity ranking of
A15S30. Although less accurate than the previous
configuration,2 this assay format furnished data of
good quality that clearly supported the above results.
Complexes of the three mAbs with A15S30 dissociated
2 Unlike the previously described SPR configuration, these assays
were not fully optimized. Ideally, to ensure a 1:1 interaction, Fab
fragments instead of whole mAbs should have been used. Analytes
such as mAbs are prone to bind under diffusion-controlled kinetics
and to cause steric hindrance effects. Also, differences in peptide
immobilization levels can make comparisons among them unreliable.
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Fig. 1. Absorbance vs. concentration plots obtained in the competition ELISA analysis of peptides A15 and A15S30.
much faster than the corresponding complexes with
A15 (Table 5, Fig. 2(C–D)).
4. Discussion
SPR biosensors allow fast and reliable screening of
antigens and provide kinetic data on antigen–antibody
interactions (Altschuh et al., 1992; Garland, 1996;
Schuck, 1997). However, artifacts such as ligand site
heterogeneity, ligand steric hindrance, mass-transport
limitations, conformational change and non-specific
binding have been identified and caution must be taken
when considering the kinetic constants as absolute val-
ues (Schuck and Minton, 1996; O’Shannessy and Win-
zor, 1996; Hall et al., 1996). Another limitation is the
size of the analyte, which should ideally be over 5 kDa
for BIAcore 1000 instruments (Karlsson, 1994). When
large numbers of small peptides are to be tested, the
conventional assay format, involving peptide immobi-
lization and injection of mAb as soluble analyte, has
several drawbacks: (1) it involves substantial costs on
mAbs, sensor chips and immobilization reagents; (2)
comparison between different peptides is not reliable,
since immobilization conditions are difficult to repro-
duce; (3) the high amounts of peptide required to
obtain measurable immobilization responses cause
problems such as ligand site heterogeneity and diffu-
sion-controlled kinetics; (4) the large size of the mAb
also favors steric hindrance and diffusion-controlled
kinetics; (5) the process is quite time-consuming.
In previous studies, we have shown that reliable SPR
screening of low molecular weight peptide analytes
(1.6 kDa) (Gomes et al., 2000a,b) can be achieved by
the ‘reverse’ assay format, where soluble peptide is
injected over a mAb surface, with standard deviations
not higher than 9% observed for the determined kinetic
constants. The use of non-specific amine coupling in the
mAb immobilization step did not seem to be a source
of ligand heterogeneity, and thus allowed to avoid
problems typical of the oriented affinity capture immo-
bilization (e.g. via the Fc using a rabbit-anti-mouse
immunoglobulin), such as surface decay due to ligand
dissociation. In the present study, the choice of mAb
immobilization has again provided self-consistent re-
sults, further confirmed by an excellent agreement with
data from parallel ELISA experiments. Moreover, since
all peptides were always injected over the same mAb
surface (for each one of the three mAbs), peptide
ranking in terms of antigenic recognition is totally
meaningful.
Deconvolution of the four-point mutation sequence
found for site A of FMDV C-S30 into single-, double-
and triple-point mutant peptides revealed a coherent
pattern. We were able to confirm earlier studies in
which replacements Ala138Thr and Leu147Val
were clearly detrimental for peptide recognition by
anti-site A mAbs (Mateu et al., 1992; Verdaguer et al.,
1998; Gomes et al., 2000a,b). Peptides containing the
Leu147Val mutation were generally weak antigens
towards all three mAbs assayed and became even worse
upon addition of the Ala138Thr mutation. The
present study clearly shows that further insertion of the
well-tolerated mutations Ala140Thr and Thr149
Ala in the 15-mer sequences is not enough to restore
antigenicity levels to those of peptides A15 (reference
strain C-S8c1) or A15Brescia (C1-Brescia strain). Possi-
bly, the tight interactions between 4C4 and FMDV
C-S30 (or peptides representing its GH loop), as seen in
previous immunological and crystallographic experi-
ments, involve an important conformational change in
the loop, not measurable in the time-scale of SPR
analysis. The kinetic rate constants for the A15S30-
mAb interactions show that although the peptide
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Fig. 2. Sensorgrams obtained in the analysis of the interactions between site A15 and A15S30 peptides and mAb 4C4: (A) A15 vs. immobilized mAb; (B) A15S30 vs. immobilized mAb; (C) 4C4
vs. immobilized A15; and (D) 4C4 vs. immobilized A15S30.
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Table 5
Kinetic data for the interactions between mAbs SD6, 4C4, 3E5 and
immobilized peptides
Mab Peptide ka/M
−1s−1 kd/s
−1 KA/M
−1
1.2×104SD6 2.5×10−4A15 5.0×107
1.8×104 –A15Bresciaa
2.9×103 1.8×10−2A15S30 1.6×105
4C4 A15 2.3×104 2.2×10−4 1.1×108
A15Bresciaa 1.8×104 – –
2.5×104 1.1×10−2A15S30 2.3×106
A153E5 1.2×105 7.3×10−4 1.7×108
− –A15Bresciab –
3.5×104 1.1×10−2 3.2×106A15S30
a Under the conditions of analysis, values of kd were too small to
provide a reliable measure and values of ka were calculated from the
slope of ks versus analyte concentration (locally fitted ks=ka×C+
kd).
b ka could not be determined due to non linearity (mass-transport
effects) of ks versus C.
promptly binds to the paratope, the complex dissociates
quite fast. Structural constraints present in the virion
may have, in this particular case, an important role in
the recognition of the loop. Therefore, presentation of
peptide A15S30 would be a key feature for peptide
antigenicity. Results using conformationally restricted
(cyclic) versions of A15S30 seem to confirm this hy-
pothesis (Gomes et al., 2001). Further investigations are
presently in progress.
A remarkable conclusion of the present work is that
SPR-derived kinetic constants seem to have a specific
significance in ligand–receptor interactions. Indeed,
affinities of the different peptide analogues towards a
same mAb, whether it was SD6, 4C4 or 3E5, were
mainly determined by the dissociation rate constant, kd
(Figs. 3 and 4). This result had been previously re-
ported in the literature (VanCott et al., 1994; England
et al., 1997). A plot of affinity (KD) versus dissociation
rate constant (kd) would be a straight line with slope
Fig. 3. Correlation between thermodynamic affinity constant KD and rate dissociation constant kd for the interactions between peptides containing
combinations of the mutations Ala138Thr, Ala140Thr, Leu147Val, T149Ala and mAbs SD6 (slope=3×10−5, r2=0.98), 4C4
(slope=4×10−6, r2=0.99) and 3E5 (slope=3×10−6, r2=0.92).
Fig. 4. Global effects of the amino acid substitutions Ala138Thr, Ala140Thr, Leu147Val, T149Ala on peptide antigenicity towards
mAbs SD6, 4C4 and 3E5 (average of the relative affinities corresponding to each peptide containing each one of the four replacements).
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equal to reciprocal the association rate constant, ka. We
did, in fact, observe this behaviour and, furthermore,
were able to see that this slope, i.e. 1/ka, depended on
the antibody assayed. This suggests a role for ka, as a
measure for the global affinity of a particular antibody
to its specific epitopes.
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